- FDA Approves Sevenfact [coagulation factor VIIa (recombinant)-jncw] for Treatment and Control of Bleeding Episodes Occurring in Adult and Adolescent Hemophilia A and B Patients with Inhibitors
- FDA Approves Sevenfact (coagulation factor VIIa [recombinant]-jncw) for Adults and Adolescents with Hemophilia A or B and Inhibitors
- Imfinzi (durvalumab) Approved in the US for Extensive-Stage Small Cell Lung Cancer
- Lilly's Taltz (ixekizumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
- FDA Approves Triferic AVNU (ferric pyrophosphate citrate), Intravenous Formulation of Triferic for Replacement of Iron and Maintenance of Hemoglobin in Hemodialysis Patients
- FDA Approves Zeposia (ozanimod) for Relapsing Forms of Multiple Sclerosis
- FDA Approves Epclusa (sofosbuvir/velpatasvir) for Children Ages 6 and Older or Weighing at Least 17 kg with Chronic Hepatitis C Infection
- FDA Approves Ofev (nintedanib) as First Treatment for Chronic Fibrosing Interstitial Lung Diseases (ILDs) with a Progressive Phenotype
- FDA Approves Ofev (Nintedanib), For The Treatment of Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype
- FDA Approves Isturisa (osilodrostat) for the Treatment of Cushing’s Disease
- FDA Approves Durysta (bimatoprost implant) to Lower Intraocular Pressure In Open-Angle Glaucoma or Ocular Hypertension Patients
- FDA Approves Pizensy (lactitol) for the Treatment of Chronic Idiopathic Constipation in Adults
- FDA Approves Sarclisa (isatuximab-irfc) for Patients with Relapsed Refractory Multiple Myeloma
- FDA Approves Advil Dual Action (ibuprofen and acetaminophen) as an Over-the-Counter Pain Treatment
- FDA Approves Nurtec ODT (rimegepant) for the Acute Treatment of Migraine in Adults